Cardea Bio inks collaboration with Siemens Healthineers

By LabPulse.com staff writers

January 10, 2022 -- Cardea Bio has signed a collaboration agreement with Siemens Healthineers' Center for Innovation in Diagnostics to evaluate the feasibility of developing real-time biosensor applications using Cardea's biosignal processing unit platform.

The two firms will work together to test capabilities of a next generation SARS-CoV-2 assay, Cardea said. The collaboration will include transferring hardware, software, and expertise from Cardea's biosignal processing platform to Siemens.

If the effort is successful, the two firms plan to expand their partnership to other areas such as the measurement of antigen and amplification-free RNA detection, according to Cardea.

Siemens Healthineers sees Q4 revenue jump 19%
Siemens Healthineers saw revenue for the company's fiscal fourth quarter jump 19% after adjustment for currency changes. The increase was driven by 11%...
Siemens partners with A1 on COVID variant tracking
Siemens Healthineers announced that it is collaborating with A1 Life Sciences to support global efforts to track variants of SARS-CoV-2.
Siemens gets FDA nod for ELF test for liver fibrosis
Siemens Healthineers has been granted marketing authorization from the U.S Food and Drug Administration (FDA) for its Enhanced Liver Fibrosis (ELF) test,...
Siemens posts strong revenue, earnings growth in Q1
Benefiting from ongoing demand for products related to the COVID-19 pandemic and recovery in its core businesses, Siemens Healthineers exceeded market...
Siemens' SARS-CoV-2 test measures neutralizing antibodies
Siemens Healthineers has announced that its SARS-CoV-2 immunoglobin G antibody test is able to measure neutralizing antibodies for the virus.

Copyright © 2022 LabPulse.com

Last Updated ls 1/10/2022 3:14:54 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current